Alnylam Pharma (ALNY) Tops Q4 EPS by 16c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $260.10 -2.26%
Revenue Growth %: +15.3%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.60), $0.16 better than the analyst estimate of ($1.76). Revenue for the quarter came in at $163.6 million versus the consensus estimate of $146.07 million.
- – Provides 2021 Combined Net Product Revenue Guidance of $610-660 Million, in addition to Collaboration & Royalty Revenue and Operating Expense Guidance –
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Braze stock tumbles 10% on weak third quarter EPS guidance
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
